Hug drug or thug drug? Ecstasy use and aggressive behavior.

Department of Sociology, Georgia State University, Atlanta, GA 30303, USA.
Violence and Victims (Impact Factor: 1.28). 02/2007; 22(1):104-19. DOI: 10.1891/088667007780482892
Source: PubMed

ABSTRACT While clinical studies have established a link between aggression and ecstasy (3,4-methylenedioxymeth-amphetamine [MDMA]), no research has attempted to explore how this link manifests itself in behavioral outcomes. In this research we examine the effects of ecstasy on aggressive and violent behavior in a sample of active users. Data were collected from 260 ecstasy users in Atlanta, Georgia. Data analysis included ordered logit regression to examine the likelihood of engaging in aggressive behavior, controlling for key predictors of aggression independent of ecstasy use. Our results indicate that those with a higher prevalence of lifetime ecstasy use exhibit higher levels of aggressive and violent behavior. However, the effect of lifetime ecstasy use differs by levels of low self-control as a measure of propensity for aggression. Those who exhibit low self-control are more affected by ecstasy use than those who do not in terms of aggression. Our findings add an important dimension to our current knowledge about the relationship between aggression and ecstasy.

1 Follower
  • Source
    Neuroscience & Biobehavioral Reviews 01/2013; 37:1466-1484. · 10.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human Psychopharmacology recently published my review into the increase in empirical knowledge about the human psychobiology of MDMA over the past 25 years (Parrott, 2013a). Deficits have been demonstrated in retrospective memory, prospective memory, higher cognition, complex visual processing, sleep architecture, sleep apnoea, pain, neurohormonal activity, and psychiatric status. Neuroimaging studies have shown serotonergic deficits, which are associated with lifetime Ecstasy/MDMA usage, and degree of neurocognitive impairment. Basic psychological skills remain intact. Ecstasy/MDMA use by pregnant mothers leads to psychomotor impairments in the children. Hence, the damaging effects of Ecstasy/MDMA were far more widespread than was realized a few years ago. In their critique of my review, Doblin et al. (2014) argued that my review contained misstatements, omitted contrary findings, and recited dated misconceptions. In this reply, I have answered all the points they raised. I have been able to refute each of their criticisms by citing the relevant empirical data, since many of their points were based on inaccurate summaries of the actual research findings. Doblin and colleagues are proponents of the use of MDMA for drug-assisted psychotherapy, and their strongest criticisms were focused on my concerns about this proposal. However, again all the issues I raised were based on sound empirical evidence or theoretical understanding. Indeed I would recommend potentially far safer co-drugs such as D-cycloserine or oxytocin. In summary, MDMA can induce a wide range of neuropsychobiological changes, many of which are damaging to humans. Copyright © 2014 John Wiley & Sons, Ltd.
    Human Psychopharmacology Clinical and Experimental 03/2014; 29(2):109-19. DOI:10.1002/hup.2390 · 1.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: MDMA has properties that may make it attractive for psychotherapy, although many of its effects are potentially problematic. These contrasting effects will be critically reviewed in order to assess whether MDMA could be safe for clinical usage. Early studies from the 1980s noted that MDMA was an entactogen, engendering feelings of love and warmth. However, negative experiences can also occur with MDMA since it is not selective in the thoughts or emotions it releases. This unpredictability in the psychological material released is similar to another serotonergic drug, LSD. Acute MDMA has powerful neurohormonal effects, increasing cortisol, oxytocin, testosterone, and other hormone levels. The release of oxytocin may facilitate psychotherapy, whereas cortisol may increase stress and be counterproductive. MDMA administration is followed by a period of neurochemical recovery, when low serotonin levels are often accompanied by lethargy and depression. Regular usage can also lead to serotonergic neurotoxicity, memory problems, and other psychobiological problems. Proponents of MDMA-assisted therapy state that it should only be used for reactive disorders (such as PTSD) since it can exacerbate distress in those with a prior psychiatric history. Overall, many issues need to be considered when debating the relative benefits and dangers of using MDMA for psychotherapy.
    Journal of psychoactive drugs 03/2014; 46(1):37-43. DOI:10.1080/02791072.2014.873690 · 1.10 Impact Factor